ATE435663T1 - Krebstherapie mit einem nukleären rezeptorliganden und einem hdac-hemmer - Google Patents
Krebstherapie mit einem nukleären rezeptorliganden und einem hdac-hemmerInfo
- Publication number
- ATE435663T1 ATE435663T1 AT05717999T AT05717999T ATE435663T1 AT E435663 T1 ATE435663 T1 AT E435663T1 AT 05717999 T AT05717999 T AT 05717999T AT 05717999 T AT05717999 T AT 05717999T AT E435663 T1 ATE435663 T1 AT E435663T1
- Authority
- AT
- Austria
- Prior art keywords
- nuclear receptor
- cancer therapy
- receptor ligand
- hdac inhibitor
- ligand
- Prior art date
Links
- 239000003446 ligand Substances 0.000 title abstract 4
- 108020005497 Nuclear hormone receptor Proteins 0.000 title abstract 3
- 102000006255 nuclear receptors Human genes 0.000 title abstract 3
- 108020004017 nuclear receptors Proteins 0.000 title abstract 3
- 238000011275 oncology therapy Methods 0.000 title abstract 3
- 229940121372 histone deacetylase inhibitor Drugs 0.000 title 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 title 1
- 102000003964 Histone deacetylase Human genes 0.000 abstract 2
- 108090000353 Histone deacetylase Proteins 0.000 abstract 2
- 206010005003 Bladder cancer Diseases 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 210000002307 prostate Anatomy 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 210000003932 urinary bladder Anatomy 0.000 abstract 1
- 201000005112 urinary bladder cancer Diseases 0.000 abstract 1
- 102000009310 vitamin D receptors Human genes 0.000 abstract 1
- 108050000156 vitamin D receptors Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0405349.2A GB0405349D0 (en) | 2004-03-10 | 2004-03-10 | Cancer therapy and medicaments therefor |
| PCT/GB2005/000938 WO2005087206A2 (en) | 2004-03-10 | 2005-03-10 | Cancer therapy comprising a nuclear receptor ligand and a hdac inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE435663T1 true ATE435663T1 (de) | 2009-07-15 |
Family
ID=32117372
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05717999T ATE435663T1 (de) | 2004-03-10 | 2005-03-10 | Krebstherapie mit einem nukleären rezeptorliganden und einem hdac-hemmer |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20090105343A1 (de) |
| EP (1) | EP1735002B1 (de) |
| AT (1) | ATE435663T1 (de) |
| AU (1) | AU2005221388B2 (de) |
| DE (1) | DE602005015304D1 (de) |
| GB (1) | GB0405349D0 (de) |
| WO (1) | WO2005087206A2 (de) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1996233A2 (de) * | 2006-02-27 | 2008-12-03 | Gilead Colorado, Inc. | Therapeutische kombinationen und verfahren zur verbesserung des herz-kreislauf-systems und behandlung einer herz-kreislauf-erkrankung |
| CA2650520A1 (en) | 2006-04-24 | 2008-01-31 | Gloucester Pharmaceuticals | Treatment of ras-expressing tumors |
| US8957027B2 (en) | 2006-06-08 | 2015-02-17 | Celgene Corporation | Deacetylase inhibitor therapy |
| EP2066355A2 (de) * | 2006-09-19 | 2009-06-10 | Braincells, Inc. | Kombination aus einem durch einen peroxisom-proliferator aktivierten rezeptor-mittel und einem zweiten neurogenen mittel zur behandlung von erkrankungen des nervensystems sowie zur förderung von neuraler differenzierung und neurogenese |
| US20080242648A1 (en) * | 2006-11-10 | 2008-10-02 | Syndax Pharmaceuticals, Inc., A California Corporation | COMBINATION OF ERa+ LIGANDS AND HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER |
| JP2010514801A (ja) * | 2006-12-29 | 2010-05-06 | グラスター ファーマシューティカルズ， インコーポレイテッド | ロミデプシンの精製 |
| CA2804795A1 (en) | 2010-07-12 | 2012-01-19 | Nicholas Vrolijk | Romidepsin solid forms and uses thereof |
| US8859502B2 (en) | 2010-09-13 | 2014-10-14 | Celgene Corporation | Therapy for MLL-rearranged leukemia |
| AU2013202506B2 (en) | 2012-09-07 | 2015-06-18 | Celgene Corporation | Resistance biomarkers for hdac inhibitors |
| AU2013202507B9 (en) | 2012-11-14 | 2015-08-13 | Celgene Corporation | Inhibition of drug resistant cancer cells |
| NZ630311A (en) | 2013-12-27 | 2016-03-31 | Celgene Corp | Romidepsin formulations and uses thereof |
| DK3253382T3 (da) * | 2015-02-06 | 2022-02-14 | Intercept Pharmaceuticals Inc | Farmaceutiske sammensætninger til kombinationsterapi |
| CN115068618A (zh) * | 2022-07-11 | 2022-09-20 | 厦门大学附属第一医院 | 一种预防和/或治疗急性髓系白血病的联合用药物组合物及其应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6262116B1 (en) * | 1998-01-23 | 2001-07-17 | Sloan-Kettering Institute For Cancer Research | Transcription therapy for cancers |
| US7175981B2 (en) * | 1998-12-01 | 2007-02-13 | The United States Of America As Represented By The Secretary Of The Army | Method of diagnosing stage or aggressiveness of breast and prostate cancer based on levels of fatty acid binding proteins |
| US20040266834A1 (en) * | 1999-10-14 | 2004-12-30 | Copland John A. | Thiazolidinediones alone or in cabination with other therapeutic agents for cancer therapy |
| US20020183388A1 (en) * | 2001-02-01 | 2002-12-05 | Gudas Lorraine J. | Use of retinoids plus histone deacetylase inhibitors to inhibit the growth of solid tumors |
| US20040044028A1 (en) * | 2001-03-30 | 2004-03-04 | Obukowicz Mark G. | Combinations of omega-3 fatty acids and cyclooxygenase-2 inhibitors for treatment or prevention of cardiovascular disease and treatment or prevention of cancer |
| US6656969B2 (en) * | 2001-09-20 | 2003-12-02 | Mayo Foundation For Medical Education And Research | Methods and compositions for inhibiting the proliferation of prostate cancer cells |
-
2004
- 2004-03-10 GB GBGB0405349.2A patent/GB0405349D0/en not_active Ceased
-
2005
- 2005-03-10 US US10/592,251 patent/US20090105343A1/en not_active Abandoned
- 2005-03-10 AT AT05717999T patent/ATE435663T1/de not_active IP Right Cessation
- 2005-03-10 EP EP05717999A patent/EP1735002B1/de not_active Not-in-force
- 2005-03-10 WO PCT/GB2005/000938 patent/WO2005087206A2/en active Application Filing
- 2005-03-10 AU AU2005221388A patent/AU2005221388B2/en not_active Ceased
- 2005-03-10 DE DE602005015304T patent/DE602005015304D1/de active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP1735002B1 (de) | 2009-07-08 |
| AU2005221388B2 (en) | 2010-03-18 |
| US20090105343A1 (en) | 2009-04-23 |
| GB0405349D0 (en) | 2004-04-21 |
| EP1735002A2 (de) | 2006-12-27 |
| DE602005015304D1 (de) | 2009-08-20 |
| WO2005087206A2 (en) | 2005-09-22 |
| WO2005087206A3 (en) | 2006-01-12 |
| AU2005221388A1 (en) | 2005-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE435663T1 (de) | Krebstherapie mit einem nukleären rezeptorliganden und einem hdac-hemmer | |
| MY174080A (en) | Use of dpp iv inhibitors | |
| MY141119A (en) | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis | |
| HK1071310A1 (en) | Combination therapy for the treatment of cancer | |
| MX2007003505A (es) | Combinacion que comprende zd6474 e imatinib. | |
| MX353964B (es) | Agentes terapeuticos y usos de los mismos. | |
| CY1111547T1 (el) | Συνδυασμος zd6474 και πεμετρεξεδης | |
| MX2013010770A (es) | Tratamiento de tumores solidos. | |
| EA200900912A1 (ru) | Специфическая терапия и лекарственное средство на основе интегриновых лигандов для лечения рака | |
| CY1111482T1 (el) | Συνδυασμος azd2171 και πεμετρεξεδης | |
| RU2013131241A (ru) | Композиции, содержащие ингибитор рi3к и ингибитор мек, а также их применение для лечения рака | |
| NO20056170L (no) | Kreftkombinasjonsterapi omfattende AZD2171 of ZD1839 | |
| ATE447974T1 (de) | Kombinationstherapie mit azd2171 und 5-fu und/oder cpt-11 | |
| NO20064753L (no) | Kombinasjonsterapi | |
| NO20056171L (no) | Kombinasjonsterapi | |
| NO20064754L (no) | Kombinasjonsterapi | |
| TW200724158A (en) | Combination therapy in the treatment of cancer | |
| NO20043774L (no) | The use of devazenide as analgesic agent | |
| UA110795C2 (uk) | Спосіб лікування раку підшлункової залози | |
| ATE339209T1 (de) | Kombinationstherapie mit gemzitabin und zd6126 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |